# OnCo record idea-tr2-biomarker-negative-arms (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr2-biomarker-negative-arms/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr2-biomarker-negative-arms" ;
  schema:name "Randomised trials to test whether biomarker-negative patients really do not benefit"@en ;
  schema:description "Patients are denied a drug when a test says they will not benefit, but that restriction is usually inferred from enrichment trials rather than tested. For high-stakes markers with weak evidence in the negative group, such as PD-L1 and HER2 0, randomised trials in biomarker-negative patients should test the assumption itself."@en ;
  schema:url <https://onco.cc/ideas/idea-tr2-biomarker-negative-arms/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2021.7239> ;
  onco:related <https://onco.cc/terms/her2-low/>, <https://onco.cc/ideas/idea-tr2-marker-stratified-default/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:trials <https://onco.cc/trials/destiny-breast06/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/>, <https://onco.cc/key-papers/paper-fernandez-jama-oncol/> .